Abstract 579P
Background
Dacomitinib demonstrated superior survival benefit compared to gefitinib as a first-line treatment in EGFR-mutant non-small cell lung cancer (NSCLC) patients through the phase 3 trial, ARCHER 1050 study. However, there is a lack of real-world data regarding the efficacy of dacomitinib and further sequential treatments after failure of dacomitinib.
Methods
This study included patients with advanced EGFR-mutant NSCLC who received first-line dacomitinib between January 2021 and December 2022 at Samsung Medical Center and St. Vincent Hospital. This study evaluated objective response rate (ORR), progression-free survival (PFS), safety of dacomitinib, and subsequential treatment after failing dacomitinib.
Results
In total, this study included 153 patients, with a median age of 63.7 years. Exon 19 deletion was observed in 50.3%, while the L858R mutation in exon 21 was observed in 46.4% of patients. The ORR was 84.3%. Median follow-up duration was 16.9 months, and the median PFS was 16.7 months (95% CI, 14.4, 25.2). According to type of EGFR mutation, the median PFS was 18.1 months (95% CI, 14.5, not reached) in patients with exon 19 deletion, and 15.9 months (95% CI, 12.5, not reached) in patients with L858R mutation in exon 21. Grade 3 or higher adverse events were observed in 7.2% of patients, with skin rash occurring in 4.6% and diarrhea in 2.0%. Dose reduction of dacomitinib occurred in 85.6% of patients, with a final dose of 30mg in 49.0% and 15mg in 36.6%. Among the 60 patients who experienced disease progression, 32 patients underwent tissue re-biopsy, while among the remaining, 24 patients underwent liquid biopsy. Overall, T790M mutation was detected in 40% of patients who progressed to dacomitinib.
Conclusions
This study highlights the efficacy of dacomitinib as a promising first-line treatment for patients with EGFR-mutant NSCLC in a real-world setting. The detection rate of T790M mutation after dacomitinib treatment failure was similar to that of other 2nd generation EGFR-TKI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Pfizer.
Disclosure
J.E. Shin: Financial Interests, Institutional, Funding: Pfizer.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract